KURA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KURA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Kura Oncology has the GF Value Rank of 0.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Kura Oncology's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian T. Powl | officer: Chief Commercial Officer | C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131 |
Thomas Malley | director | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Thomas James Doyle | officer: SVP, Finance & Accounting | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Kirsten Flowers | officer: Chief Commercial Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Kathleen Ford | officer: Chief Operating Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Stephen Dale | officer: Chief Medical Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Teresa Brophy Bair | officer: Chief Legal Officer | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Helen Louise Collins | director | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Carol Schafer | director | 42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013 |
Troy Edward Wilson | director, officer: President and CEO | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Marc Grasso | officer: CFO, CBO | C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121 |
Bridget A Martell | officer: Acting Chief Medical Officer | C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
James Basta | officer: Chief Legal Officer | C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121 |
Diane L. Parks | director | 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540 |
Antonio Gualberto | officer: Chief Medical Officer | 245 FIRST STREET, SUITE 1820, CAMBRIDGE MA 02142 |
From GuruFocus
By sperokesalga sperokesalga • 04-18-2023
By Marketwired • 11-02-2023
By Marketwired • 10-17-2023
By sperokesalga sperokesalga • 02-16-2023
By sperokesalga sperokesalga • 02-09-2023
By GlobeNewswire GlobeNewswire • 06-11-2023
By sperokesalga sperokesalga • 06-13-2023
By Marketwired • 10-04-2023
By Marketwired • 10-26-2023
By Marketwired • 10-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.